Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix to Raise Additional $1.2M in Series C Financing

NEW YORK (GenomeWeb News) – CombiMatrix will net an additional $1.2 million in funding after its stockholders approved the sale of the company's Series C Preferred Stock, the company said today.

CombiMatrix raised $1.2 million in a first tranche of equity financing in May. The second tranche of that financing was subject to stockholder approval, which was granted at the firm's annual meeting, held on June 27.

The proceeds from the two tranches total $2.4 million, providing the molecular diagnostics company with cash and cash equivalent balances of $5.6 million, as of June 30.

CombiMatrix's latest financing coincides with some concern about the Irvine, Calif.-based firm's balance sheet. Nasdaq recently extended a deadline until Aug. 20 for the firm to meet the exchange's requirement for $2.5 million in stockholder's equity to retain its listing.

Also, during the company's fourth-quarter 2012 earnings call in February, a Wall Street analyst noted that given the company's burn rate, it could run out of cash by summer. Former CEO Judd Jessup had responded that the firm would do a "number of things" to generate capital, and that he was optimistic that the firm would be able to raise additional money.

The recently concluded round of financing was through the sale of convertible preferred stock, CombiMatrix said. Both tranches had a conversion price of $2.85759 per common share, subject to future adjustments, as well as 125 percent warrant coverage. The first tranche of warrants had an exercise price of $3.77 per share and the second tranche of warrants had an exercise price of $3.55 per share.

Shares of CombiMatrix were trading at $3.00 on Monday morning, down roughly 6 percent from a previous close of $3.18.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.